Document Detail


The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
MedLine Citation:
PMID:  20430305     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The development of biologics has dramatically altered the treatment of moderate-to-severe psoriasis while also introducing new standards of care for therapeutic monitoring. Currently, the biologics approved by the US Food and Drug Administration are divided into 3 classes: T-cell modulators, tumor necrosis factor-alpha inhibitors, and interleukin-12/23 inhibitors. Although the US Food and Drug Administration has established recommendations for pre- and peri-treatment screening evaluations, much of the evidence comes from clinical trials evaluating the short-term safety and efficacy of each medication, rather than long-term data, or studies that summarize either the appropriateness or feasibility of screening. Instead of following a blanket algorithm, providers must understand the evidence as it relates to each medication to determine which tests are appropriate for any specific patient. This chapter summarizes the current body of evidence and recommends a practical approach for monitoring psoriasis patients who are receiving biologic therapies.
Authors:
Danielle Levine; Bruce E Strober
Related Documents :
1001525 - The acceptance of the collagen sponge diaphragm as an intravaginal contraceptive in hum...
19060725 - Are topical antimicrobials effective against bacteria that are highly resistant to syst...
497075 - Has droperidol an atropinic effect?
16212145 - Psychological effect, pathophysiology, and management of androgenetic alopecia in men.
20216465 - Physical activity and food consumption in high- and low-active inbred mouse strains.
11794665 - Analysis of sludge management parameters resulting from the use of domestic garbage dis...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in cutaneous medicine and surgery     Volume:  29     ISSN:  1558-0768     ISO Abbreviation:  Semin Cutan Med Surg     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-04-30     Completed Date:  2010-08-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9617260     Medline TA:  Semin Cutan Med Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  28-34     Citation Subset:  IM    
Affiliation:
Tufts University School of Medicine, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents / therapeutic use*
Biological Products / therapeutic use*
Dermatologic Agents / therapeutic use*
Drug Monitoring
Humans
Immunologic Factors / therapeutic use*
Psoriasis / diagnosis*,  drug therapy*,  etiology
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Biological Products; 0/Dermatologic Agents; 0/Immunologic Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessing long-term drug safety: lessons (re) learned from raptiva.
Next Document:  Safety and efficacy of the tumor necrosis factor antagonists.